ID: h-9e877c49ba
Hypothesis
Physiological SCFAs may worsen alpha-synuclein pathology through FFAR2/GPR43-NLRP3 inflammatory signaling and impaired microglial handling
A key liability hypothesis is that low-range SCFA signaling can be receptor-biased toward inflammasome activation in susceptible contexts, increasing IL-1beta and neuroinflammation rather than aggregate disposal.
EvidencePending (0%)📖 7 cit🗣 1 debates✓ 7 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
A key liability hypothesis is that low-range SCFA signaling can be receptor-biased toward inflammasome activation in susceptible contexts, increasing IL-1beta and neuroinflammation rather than aggregate disposal. This is not a development thesis, but it is a high-priority safety gate because it could explain why physiologic SCFA elevation is ineffective or harmful in some synucleinopathy settings.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["FFAR2/GPR43<br/>High SCFA Affinity Receptor"]
B["Acetate-Driven Activation<br/>G-protein Coupling"]
C["PI3K/AKT Pathway<br/>Anti-apoptotic Signaling"]
D["NLRP3 Inhibition<br/>Anti-inflammatory Effect"]
E["Microglial Homeostasis<br/>M2 Polarization"]
F["Gut Microbiome Dysbiosis<br/>SCFA Depletion"]
G["Synaptic Integrity<br/>Support of Neuronal Function"]
H["Neuroinflammation<br/>Pro-inflammatory Shift"]
I["Cognitive Decline<br/>AD and Related Dementias"]
A --> B
B --> C
C --> D
D --> E
E --> G
F --> H
H --> I
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style I fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
⚖️ Evidence Matrix7 supports2 contradicts
Supports
Gut microbial SCFAs promoted motor deficits, microglial activation, and alpha-syn pathology in a synucleinopathy mouse model.
Supports
A newer study linked SCFA-driven pathology to GPR43-NLRP3 signaling, directly supporting an inflammatory liability mechanism.
Supports
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Supports
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
Supports
ASC specks exacerbate α‑synuclein pathology via amplifying NLRP3 inflammasome activities.
Supports
Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
Contradicts
These models are context-dependent and do not establish that confirmed physiologic human-equivalent micromolar exposure will impair microglial aggregate clearance in vivo.
Contradicts
Worsened phenotype could arise from peripheral immune or gut effects rather than direct failure of microglial alpha-syn disposal.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — FFAR2
No curated PDB or AlphaFold mapping for FFAR2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for FFAR2/NLRP3/IL1B from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for FFAR2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.2%
Volatility
Low
0.0045
Events (7d)
2
Price History
▼3.0%💾 Resource Usage
LLM Tokens
19,114
$0.0573
Total Cost
$0.0573
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF adult male M83 alpha-synuclein transgenic mice receive continuous oral supplementation with a low-dose SCFA mixture (propionate 20mM, acetate 30mM, butyrate 10mM in drinking water) for 12 weeks, TH | 30% increase in IL-1beta and 25% increase in pSyn+ aggregate burden | — no observation — | pending | 0.60 |
| IF aged (12-month) alpha-synuclein transgenic mice (Thy1-SNCA) are treated with a selective FFAR2 antagonist (CATPB, 10mg/kg i.p. daily) for 8 weeks during high SCFA exposure (propionate 40mM in drink | 40% decrease in microglial IL-1beta and 15-second improvement in motor performance | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 60%
IF adult male M83 alpha-synuclein transgenic mice receive continuous oral supplementation with a low-dose SCFA mixture (propionate 20mM, acetate 30mM, butyrate 10mM in drinking water) for 12 weeks, THEN brain tissue IL-1beta protein levels will increase by ≥30% and stereological counts of pSyn+ aggr
Predicted outcome: 30% increase in IL-1beta and 25% increase in pSyn+ aggregate burden
Falsification: SCFA treatment causes no change or a decrease in IL-1beta and pSyn+ aggregates compared to vehicle control
pendingconf 55%
IF aged (12-month) alpha-synuclein transgenic mice (Thy1-SNCA) are treated with a selective FFAR2 antagonist (CATPB, 10mg/kg i.p. daily) for 8 weeks during high SCFA exposure (propionate 40mM in drinking water), THEN microglial IL-1beta release ex vivo will decrease by ≥40% and rotarod latency will
Predicted outcome: 40% decrease in microglial IL-1beta and 15-second improvement in motor performance
Falsification: FFAR2 antagonism fails to reduce IL-1beta or does not improve motor deficits despite SCFA exposure
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.